Cargando…

Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience

INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohd, Rozita, Mohammad Kazmin, Nur Ezzaty, Abdul Cader, Rizna, Abd Shukor, Nordashima, Wong, Yin Ping, Shah, Shamsul Azhar, Alfian, Nurwardah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432/
https://www.ncbi.nlm.nih.gov/pubmed/33831052
http://dx.doi.org/10.1371/journal.pone.0249592
_version_ 1783676163784179712
author Mohd, Rozita
Mohammad Kazmin, Nur Ezzaty
Abdul Cader, Rizna
Abd Shukor, Nordashima
Wong, Yin Ping
Shah, Shamsul Azhar
Alfian, Nurwardah
author_facet Mohd, Rozita
Mohammad Kazmin, Nur Ezzaty
Abdul Cader, Rizna
Abd Shukor, Nordashima
Wong, Yin Ping
Shah, Shamsul Azhar
Alfian, Nurwardah
author_sort Mohd, Rozita
collection PubMed
description INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and the factors affecting it. METHODS: This study included all biopsy-proven IgAN patients with ≥ 1year follow-up. Patients with diabetes mellitus at diagnosis and secondary IgAN were excluded. Medical records were reviewed for demographics, clinical presentation, blood pressure, 24-hour urine protein, serum creatinine, renal biopsy and treatment received. The primary outcome was defined as combined event of 50% estimated glomerular filtration rate (eGFR) reduction or ESRD. RESULTS: We included 130 (74 females; 56 males) patients of mean age 38.0 ± 14.0 years and median eGFR of 75.2 (interquartile range (IQR) 49.3–101.4) ml/min/1.73m(2). Eighty-four (64.6%) were hypertensive at presentation, 35 (26.9%) had nephrotic syndrome and 57 (43.8%) had nephrotic range proteinuria (NRP). Median follow-up duration was 7.5 (IQR 4.0–13.0) years. It was noted that 18 (13.8%) developed ESRD and 34 (26.2%) reached the primary outcome. Annual eGFR decline was -2.1 (IQR -5.3 to -0.1) ml/min/1.73m2/year, with median survival of 20 years. Survival rates from the combined event (50% decrease in eGFR or ESRD) at 10, 20 and 30 years were 80%, 53% and 25%, while survival from ESRD were 87%, 73% and 65%, respectively. In the univariate analysis, time-average proteinuria (hazard ratio (HR) = 2.41, 95% CI 1.77–3.30), eGFR <45ml/min/1.73m2 at biopsy (HR = 2.35, 95% CI 1.03–5.32), hypertension (HR = 2.81, 95% CI 1.16–6.80), mean arterial pressure (HR = 1.02, 95% CI 1.01–1.04), tubular atrophy/interstitial fibrosis score (HR = 3.77, 95% CI 1.84–7.73), and cellular/fibrocellular crescent score (HR = 2.44, 95% CI 1.19–5.00) were found to be significant. Whereas only time-average proteinuria (TA-proteinuria) remained as a significant predictor in the multivariate analysis (HR = 2.23, 95% CI 1.57–3.16). CONCLUSION: In our cohort, TA-proteinuria was the most important predictor in the progression of IgAN, irrespective of degree of proteinuria at presentation.
format Online
Article
Text
id pubmed-8031432
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-80314322021-04-14 Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience Mohd, Rozita Mohammad Kazmin, Nur Ezzaty Abdul Cader, Rizna Abd Shukor, Nordashima Wong, Yin Ping Shah, Shamsul Azhar Alfian, Nurwardah PLoS One Research Article INTRODUCTION: IgA nephropathy (IgAN) has a heterogeneous presentation and the progression to end stage renal disease (ESRD) is often influenced by demographics, ethnicity, as well as choice of treatment regimen. In this study, we investigated the long term survival of IgAN patients in our center and the factors affecting it. METHODS: This study included all biopsy-proven IgAN patients with ≥ 1year follow-up. Patients with diabetes mellitus at diagnosis and secondary IgAN were excluded. Medical records were reviewed for demographics, clinical presentation, blood pressure, 24-hour urine protein, serum creatinine, renal biopsy and treatment received. The primary outcome was defined as combined event of 50% estimated glomerular filtration rate (eGFR) reduction or ESRD. RESULTS: We included 130 (74 females; 56 males) patients of mean age 38.0 ± 14.0 years and median eGFR of 75.2 (interquartile range (IQR) 49.3–101.4) ml/min/1.73m(2). Eighty-four (64.6%) were hypertensive at presentation, 35 (26.9%) had nephrotic syndrome and 57 (43.8%) had nephrotic range proteinuria (NRP). Median follow-up duration was 7.5 (IQR 4.0–13.0) years. It was noted that 18 (13.8%) developed ESRD and 34 (26.2%) reached the primary outcome. Annual eGFR decline was -2.1 (IQR -5.3 to -0.1) ml/min/1.73m2/year, with median survival of 20 years. Survival rates from the combined event (50% decrease in eGFR or ESRD) at 10, 20 and 30 years were 80%, 53% and 25%, while survival from ESRD were 87%, 73% and 65%, respectively. In the univariate analysis, time-average proteinuria (hazard ratio (HR) = 2.41, 95% CI 1.77–3.30), eGFR <45ml/min/1.73m2 at biopsy (HR = 2.35, 95% CI 1.03–5.32), hypertension (HR = 2.81, 95% CI 1.16–6.80), mean arterial pressure (HR = 1.02, 95% CI 1.01–1.04), tubular atrophy/interstitial fibrosis score (HR = 3.77, 95% CI 1.84–7.73), and cellular/fibrocellular crescent score (HR = 2.44, 95% CI 1.19–5.00) were found to be significant. Whereas only time-average proteinuria (TA-proteinuria) remained as a significant predictor in the multivariate analysis (HR = 2.23, 95% CI 1.57–3.16). CONCLUSION: In our cohort, TA-proteinuria was the most important predictor in the progression of IgAN, irrespective of degree of proteinuria at presentation. Public Library of Science 2021-04-08 /pmc/articles/PMC8031432/ /pubmed/33831052 http://dx.doi.org/10.1371/journal.pone.0249592 Text en © 2021 Mohd et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Mohd, Rozita
Mohammad Kazmin, Nur Ezzaty
Abdul Cader, Rizna
Abd Shukor, Nordashima
Wong, Yin Ping
Shah, Shamsul Azhar
Alfian, Nurwardah
Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title_full Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title_fullStr Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title_full_unstemmed Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title_short Long term outcome of immunoglobulin A (IgA) nephropathy: A single center experience
title_sort long term outcome of immunoglobulin a (iga) nephropathy: a single center experience
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031432/
https://www.ncbi.nlm.nih.gov/pubmed/33831052
http://dx.doi.org/10.1371/journal.pone.0249592
work_keys_str_mv AT mohdrozita longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT mohammadkazminnurezzaty longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT abdulcaderrizna longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT abdshukornordashima longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT wongyinping longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT shahshamsulazhar longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience
AT alfiannurwardah longtermoutcomeofimmunoglobulinaiganephropathyasinglecenterexperience